Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Nkarta, Inc.NASDAQ: NKTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$2.34M, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$2.34M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$2.34M or moves back toward the trailing-twelve-month quarterly average of -$585K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.34M— QoQ
Last fiscal yearDec 2025
-$9.19M— YoY
LTMMar 2026
-$2.34M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(9.19M) USD
Year-over-year change
—

Gross Profit vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
NKTX Competitors
Gross Profit for NKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBRXForte Biosciences, Inc.LTM Mar 2026-$6K USD+86.0%——
VORVor Biopharma Inc.LTM Mar 2026-$28K USD+98.4%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
ALECAlector, Inc.LTM Mar 2026-$11.28M USD-289.4%-56.0%61.2%
FATEFate Therapeutics, Inc.LTM Mar 2026-$26.26M USD+63.7%—415.8%
Peer median (excluding NKTX) —+75.2%-56.0%238.5%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue005.87M09.19M
Gross Profit00(5.87M)0(9.19M)
Gross Margin—————
Research & Development63.41M90.9M90.9M96.74M90.43M
Selling, General & Admin23.02M28.06M34.88M31.45M31.57M
Operating Expenses86.43M118.96M125.78M128.19M112.01M
Depreciation & Amortization1.76M2.64M5.87M9.15M9.19M
EBITDA(84.32M)(105.61M)(120.48M)(99.64M)(94.89M)
EBITDA Margin—————
Operating Income(86.43M)(118.96M)(131.65M)(128.19M)(121.21M)
Operating Margin—————
Interest Income370K5.59M14.11M19.32M15.49M
Interest Expense05.59M000
Other Income / Expenses354K5.12M14.15M19.4M17.12M
Income Before Tax(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Net Margin—————
EPS (Basic)(2.62)(2.61)(2.40)(1.60)(1.41)
EPS (Diluted)(2.62)(2.61)(2.40)(1.60)(1.41)
Weighted Avg Shares32.86M43.63M49.01M67.87M73.99M
Weighted Avg Shares (Diluted)32.86M43.63M49.01M67.87M73.99M

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.